Intuitive Surgical’s Earnings Beat Could Not Hide a U.S. Slowdown

Intuitive Surgical delivered a third-quarter earnings beat, yet the stock fell because the details pointed to weaker economics in its most important recurring business. Adjusted earnings were $3.00 a share on revenue of $3.05 billion, above cited consensus estimates of $2.65 and $2.91 billion. The headline beat was not the issue. The mix of procedure growth and planned pricing was.

U.S. da Vinci procedure volume rose 10%, while international procedures increased 20%. That divergence matters because the United States is Intuitive’s largest and most developed market. A slower domestic pace can limit the growth of instruments and accessories, which are purchased for each procedure and form a recurring revenue stream around the installed robot base.

Management also plans to reduce instrument and accessory revenue per procedure by roughly 3% to 5% at constant mix once the changes are fully implemented by the end of 2027. Lower prices may support adoption and customer economics, but they also require more procedure growth to produce the same revenue. The market reaction suggests investors are recalculating that trade-off rather than questioning demand for robotic surgery itself.

The quarter also included a $450 million pretax charge tied to an antitrust settlement. GAAP net income fell to $523 million, or $1.49 per diluted share, from $1.95 a year earlier. That charge is distinct from operating demand, but it cannot be ignored when assessing reported profit and cash claims. Adjusted earnings exclude the item, which explains part of the gap between the strong adjusted result and weaker GAAP comparison.

Intuitive maintained a full-year procedure growth outlook of 14% to 15%. That guidance still implies healthy system use, and the 20% international increase shows expansion outside the United States. The tension is that investors have valued Intuitive partly for predictable recurring growth, so a domestic slowdown plus lower revenue per procedure changes the slope of that model even if total procedures keep rising.

The next useful checks are U.S. procedure growth, the pace of international expansion and management’s implementation timeline for the price reductions. Investors should also compare reported and adjusted profit separately because the settlement charge is material but not a recurring measure of surgical demand. The quarter did not break Intuitive’s business model. It did show that continued volume growth will have to work harder to offset softer domestic momentum and lower pricing.